XNASINM
Market cap3mUSD
Dec 23, Last price
4.68USD
1D
6.39%
1Q
1,912.90%
Jan 2017
-96.66%
Name
InMed Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
0.73
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
104.91%
Rev. gr., 5y
%
Revenues
5m
+11.18%
Net income
-8m
L-3.42%
CFO
-7m
L-4.08%
Earnings
Feb 11, 2025
Profile
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | 2015‑06 | |
| Income | ||||||||||
Revenues | 4,598 11.18% | 4,136 279.61% | 1,089 | |||||||
Cost of revenue | 12,513 | 12,312 | 14,696 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (7,915) | (8,177) | (13,606) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | 7 | 13 | 4,808 | |||||||
Tax Rate | ||||||||||
NOPAT | (7,922) | (8,190) | (18,414) | |||||||
Net income | (7,676) -3.42% | (7,948) -57.27% | (18,600) 82.35% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 4,654 | 10,680 | 17,146 | |||||||
BB yield | -231.09% | -470.80% | -10.40% | |||||||
| Debt | ||||||||||
Debt current | 318 | 376 | 404 | |||||||
Long-term debt | 1,608 | 408 | 1,183 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | (4,689) | (8,129) | (4,634) | |||||||
| Cash flow | ||||||||||
Cash from operating activities | (6,986) | (7,283) | (15,584) | |||||||
CAPEX | (162) | (39) | ||||||||
Cash from investing activities | (9) | (662) | (673) | |||||||
Cash from financing activities | 4,654 | 10,681 | 15,070 | |||||||
FCF | (6,947,651) | 6,931,233 | (19,453) | |||||||
| Balance | ||||||||||
Cash | 6,615 | 8,913 | 6,222 | |||||||
Long term investments | ||||||||||
Excess cash | 6,385 | 8,706 | 6,167 | |||||||
Stockholders' equity | (26,163) | (23,651) | (22,606) | |||||||
Invested Capital | 36,332 | 2,035,671 | 32,478 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | 7,585 | 2,448 | 14,021 | |||||||
Price | 0.27 -71.34% | 0.93 -92.12% | 11.76 -85.21% | |||||||
Market cap | 2,014 -11.22% | 2,268 -98.62% | 164,884 668.15% | |||||||
EV | (2,675) | (5,861) | 160,250 | |||||||
EBITDA | (7,310) | (7,581) | (13,094) | |||||||
EV/EBITDA | 0.37 | 0.77 | ||||||||
Interest | 96 | |||||||||
Interest/NOPBT | ||||||||||